A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors

Por James J. Harding, Ignacio Garrido-Laguna, Xiaoying Chen, Cynthia Basu, Afshin Dowlati, Alison Forgie, Andrea T. Hooper, Cris Kamperschroer, Steven I. Max, Steven I. Max, Allison Moreau, Megan Shannon, Gilbert Y. Wong, David S. Hong
Publicado em 2022-04-01